发布求助
文献互助 智能选刊 最新文献

European journal of rheumatology and inflammation最新文献

筛选
英文 中文
The NSAID patch. NSAID贴片。
European journal of rheumatology and inflammation Pub Date : 1994-01-01
R Grahame
{"title":"The NSAID patch.","authors":"R Grahame","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"14 4","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18605816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the efficacy and tolerability of a new locally acting preparation of flurbiprofen in scapulohumeral periarthritis. 一种新的局部作用氟比洛芬制剂治疗肩周炎的疗效和耐受性评价。
European journal of rheumatology and inflammation Pub Date : 1994-01-01
L Mattara, F Trotta, D Biasi, R Cervetti
{"title":"Evaluation of the efficacy and tolerability of a new locally acting preparation of flurbiprofen in scapulohumeral periarthritis.","authors":"L Mattara,&nbsp;F Trotta,&nbsp;D Biasi,&nbsp;R Cervetti","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This randomised, double-blind, placebo-controlled, parallel-group trial was carried out to assess the efficacy and tolerability of a new, locally acting, transcutaneous flurbiprofen preparation (flurbiprofen LATTM, Boots Company PLC) in the treatment of scapulohumeral periarthritis. The new preparation consists of a nonwoven polyester patch supporting a mentholated formulation containing flurbiprofen 40 mg. Eighty patients suffering from the acute, painful phase of scapulohumeral periarthritis entered the trial, three of which failed to provide follow-up data. Each patient applied one patch every 12 hours for the 14 day trial period. Efficacy was assessed in terms of reduction of pain, improvement in shoulder movement and overall clinical assessment of the severity of the condition after treatment. Statistically significant improvements from baseline were observed in both treatment groups, with a constant overall trend in favour of flurbiprofen. The differences between the two treatment groups, however, did not reach statistical significance.</p>","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"14 4","pages":"15-20"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18605817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical performance of etodolac in patients with osteoarthritis and rheumatoid arthritis. 依托度酸治疗骨关节炎和类风湿关节炎的临床疗效。
European journal of rheumatology and inflammation Pub Date : 1994-01-01
E M Veys
{"title":"Clinical performance of etodolac in patients with osteoarthritis and rheumatoid arthritis.","authors":"E M Veys","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The effectiveness of etodolac in the treatment of patients with osteoarthritis (OA) and with rheumatoid arthritis (RA) has been well documented in controlled clinical trials. The superiority of etodolac, 300 mg twice daily, over placebo has already been established in short-term trials involving patients with OA. During long-term treatment, significant (p < 0.05) improvement was observed in patients with OA and RA as measured by a variety of efficacy parameters. In comparative studies for OA, etodolac was more effective than conventional indomethacin; naproxen, sustained-release diclofenac, and piroxicam were comparably effective. The newer sustained-release formulation of etodolac is as effective as the conventional etodolac formulation when used to treat patients with OA and those with RA.</p>","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"14 1","pages":"23-7"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18744880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Flurbiprofen local action transcutaneous (LAT): clinical evaluation in the treatment of acute ankle sprains. 经皮氟比洛芬局部作用治疗急性踝关节扭伤的临床评价。
European journal of rheumatology and inflammation Pub Date : 1994-01-01
R L Dreiser, R Roche, R De Sahb, F Thomas, E Leutenegger
{"title":"Flurbiprofen local action transcutaneous (LAT): clinical evaluation in the treatment of acute ankle sprains.","authors":"R L Dreiser,&nbsp;R Roche,&nbsp;R De Sahb,&nbsp;F Thomas,&nbsp;E Leutenegger","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>One hundred and thirty-one male and female outpatients, aged 18-70 yr, with acute pain in the ankle joint caused by a post-traumatic sprain, entered a multicentre, randomised, double-blind, parallel-group, study. The patients were assigned to a 40 mg flurbiprofen patch (n = 65) or a non-medicated (but otherwise identical) control (n = 66), 12-hourly over 7 days, and were assessed at entry and after 3 and 7 days treatment. On day 7, spontaneous pain (the prime efficacy parameter), as evaluated by the patient on a visual analogue scale in the physician's office, showed significant improvement in the 40 mg flurbiprofen patch group compared to control (change from baseline) (p = 0.039), a result corroborated by the evaluation of the periarticular oedema: a reduction of 77.4% was observed in the 40 mg flurbiprofen patch group, compared with 63.8% in the control group (p = 0.025). The other selected efficacy criteria showed changes with a trend in favour of the 40 mg flurbiprofen patch but without statistical significance. Two mild and local adverse events were reported by two flurbiprofen patch patients, but neither patients discontinued the treatment prematurely. Physicians and patients found the flurbiprofen patch to be efficacious and well tolerated. Compliance was excellent in both groups. The efficacy and tolerability of the 40 mg flurbiprofen patch are therefore confirmed in the treatment of acute ankle sprains.</p>","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"14 4","pages":"9-13"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18548947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emergency hospital admissions. 急诊入院
European journal of rheumatology and inflammation Pub Date : 1994-01-01
A L Blower
{"title":"Emergency hospital admissions.","authors":"A L Blower","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"14 3 Suppl","pages":"11-2"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18564288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multi-centre double-blind study to define the most favourable dose of nimesulide in terms of efficacy/safety ratio in the treatment of osteoarthritis. 多中心双盲研究确定尼美舒利治疗骨关节炎的疗效/安全性的最佳剂量。
European journal of rheumatology and inflammation Pub Date : 1994-01-01
P Bourgeois, R L Dreiser, M G Lequesne, A Macciocchi, T Monti
{"title":"Multi-centre double-blind study to define the most favourable dose of nimesulide in terms of efficacy/safety ratio in the treatment of osteoarthritis.","authors":"P Bourgeois,&nbsp;R L Dreiser,&nbsp;M G Lequesne,&nbsp;A Macciocchi,&nbsp;T Monti","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A parallel group study for one month of 392 patients was undertaken to define the optimal dose of nimesulide for the treatment of painful osteoarthritis (OA). By the final visit, the mean values for pain intensity for the nimesulide groups (50 mg, 100 mg and 200 mg bd) were similar and significantly lower than the mean for the placebo group. The onset of analgesia was rapid and continued throughout the 12-hour period after drug intake, a significant analgesic effect was demonstrated with nimesulide 100 mg and 200 mg within 1.5 hours. The patients' and the physicians' overall judgements of the drug efficacy demonstrated significant differences between the treatment groups with the most successful outcomes occurring with nimesulide 100 mg and 200 mg. Nimesulide 50 mg and 100 mg were generally well-tolerated but at the highest dose level, nimesulide 200 mg, the incidence of adverse events was greater although not significantly. Results of this study demonstrate nimesulide 100 mg twice daily to be the optimal dose for the treatment of OA.</p>","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"14 2","pages":"39-50"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18744814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacokinetic profile of etodolac in special populations. 依托多拉酸在特殊人群中的药代动力学特征。
European journal of rheumatology and inflammation Pub Date : 1994-01-01
L Z Benet
{"title":"Pharmacokinetic profile of etodolac in special populations.","authors":"L Z Benet","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The pharmacokinetics of etodolac in healthy normal volunteers has been extensively studied and is well described. Etodolac is characterised by a high oral bioavailability, low clearance, a small volume of distribution, and a 7-hour half-life. It is essentially completely metabolised, therefore little is excreted unchanged. Etodolac is highly protein bound. To investigate the effect of disease states or concomitant drug administration on a patient's response to etodolac, additional pharmacokinetic studies were carried out in special populations. Since etodolac has a well-defined pharmacokinetic-pharmacodynamic relationship, measurement of pharmacokinetic parameters is clinically relevant. Data from studies to date show that disease states, underlying conditions, and concomitantly administered highly protein-bound drugs have essentially no effect on etodolac pharmacokinetics. Therefore, etodolac can generally be given without the need for dosage modifications in special populations such as uncompromised elderly patients, those with moderate renal impairment, and patients with stable hepatic disease.</p>","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"14 1","pages":"15-8"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18744878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety profile of etodolac in the elderly population. 依托度酸在老年人群中的安全性分析。
European journal of rheumatology and inflammation Pub Date : 1994-01-01
P A Bacon
{"title":"Safety profile of etodolac in the elderly population.","authors":"P A Bacon","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A growing proportion of patients who require nonsteroidal anti-inflammatory drug (NSAID) therapy are elderly. Data from patients 65 years and older with osteoarthritis or rheumatoid arthritis show that etodolac is as well tolerated in elderly as in younger patients. Of 273 elderly patients treated with at least 600 mg daily, only 12% withdrew because of adverse events, a rate similar to that in the younger age-group. Notably, the incidence of etodolac-associated gastrointestinal events is no higher in elderly than in younger patients. Etodolac was no different from diclofenac and piroxicam regarding incidence and type of adverse events. In both short- and long-term studies, the 400-mg and 600-mg sustained-release etodolac formulations were well tolerated in elderly and younger patients. Thus, etodolac appears to be a first-line choice in elderly patients.</p>","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"14 1","pages":"19-22"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18744879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of tendinitis and bursitis: a comparison of nimesulide and naproxen sodium in a double-blind parallel trial. 治疗肌腱炎和滑囊炎:尼美舒利和萘普生钠在双盲平行试验中的比较。
European journal of rheumatology and inflammation Pub Date : 1994-01-01
J Lecomte, H Buyse, J Taymans, T Monti
{"title":"Treatment of tendinitis and bursitis: a comparison of nimesulide and naproxen sodium in a double-blind parallel trial.","authors":"J Lecomte,&nbsp;H Buyse,&nbsp;J Taymans,&nbsp;T Monti","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The clinical efficacy and the tolerability of nimesulide (100 mg bid) and naproxen sodium (550 mg bid) in the treatment of tendinitis and bursitis were evaluated in a multicentre double-blind study over a 14-day period. Two hundred and five patients were included in the study. Patients randomised to one of two parallel treatment groups. They were clinically examined at days 1, 7 and 14. Blood analysis was performed at day 1 and at the end of the treatment. The main efficacy criterion was the diminution of pain during active mobilisation measured using a visual analogue scale. The improvement of the scores was obvious and similar between the two groups. The secondary efficacy criteria (pain during motion against resistance, functional impairment and global assessment of efficacy) confirmed these favourable results and did not evidence any statistical difference between the two groups. The side effects observed were mainly gastrointestinal. Their frequency and intensity were slightly higher in the naproxen sodium group but without any statistically significant difference (28 complaints in 16 patients in the nimesulide group and 33 complaints in 22 patients in the naproxen group). There was no statistical difference between the two treated groups regarding the general clinical examination and the biological follow-up.</p>","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"14 4","pages":"29-32"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18605819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Topical antirheumatic drug therapy: current practice and future trends. 局部抗风湿药物治疗:目前的实践和未来的趋势。
European journal of rheumatology and inflammation Pub Date : 1994-01-01
R L Dreiser
{"title":"Topical antirheumatic drug therapy: current practice and future trends.","authors":"R L Dreiser","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":12056,"journal":{"name":"European journal of rheumatology and inflammation","volume":"14 4","pages":"3-8"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18605820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信